Health Catalyst Reports Q3 Revenue of $76.3 Million and Net Loss of $22.2 Million

Reuters11-11
<a href="https://laohu8.com/S/HCAT">Health Catalyst</a> Reports Q3 Revenue of $76.3 Million and Net Loss of $22.2 Million

Health Catalyst Inc. reported third quarter 2025 financial results with total revenue of $76.3 million, nearly unchanged from the $76.4 million reported in the same period of 2024. Gross profit rose by 8% to $30.0 million, with gross margin increasing to 39% from 36%. The company recorded a net loss of $22.2 million, compared to a net loss of $14.7 million in the third quarter of 2024. Adjusted gross profit grew by 11% to $40.1 million, and adjusted gross margin improved to 53% from 48%. Adjusted EBITDA increased by 64% to $12.0 million. Health Catalyst reaffirmed its full-year 2025 guidance, expecting total revenue of approximately $310.0 million and adjusted EBITDA of around $41.0 million. The company highlighted its focus on high-impact solutions, strategic focus, cost management, and targeted investments as key business developments for the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Health Catalyst Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572808-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment